PHARMARON (SAN DIEGO) LAB SERVICES LLC

PHARMARON (SAN DIEGO) LAB SERVICES LLC specializes in preclinical and clinical laboratory services supporting pharmaceutical and biotechnology research and development. Their core capabilities include bioanalytical method development, sample analysis, pharmacokinetics, toxicology testing, and biomarker validation using validated chromatographic, mass spectrometric, and immunoassay platforms. The company provides end-to-end laboratory support for drug discovery and regulatory submission packages, with technical expertise in GLP- and GCP-compliant data generation, sample chain-of-custody protocols, and validated instrumentation such as LC-MS/MS and ELISA systems. Their differentiation lies in precision-driven assay validation, regulatory readiness, and scalable laboratory operations tailored to sponsor-driven timelines in early-phase drug development. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal contract work can be inferred. The absence of recent award data prevents identification of any consistent government client relationships or mission-specific program support. The primary NAICS code 541714 corresponds to laboratory services in the life sciences sector, indicating a focus on contract research organization (CRO) activities for drug development. This includes analytical testing, data reporting, and quality-controlled sample processing for sponsors navigating FDA and international regulatory pathways. The company is positioned as a specialized service provider within the preclinical research ecosystem, serving pharmaceutical and biotech clients requiring high-integrity laboratory data. PHARMARON (SAN DIEGO) LAB SERVICES LLC is structured as a small business under the 2K classification and is headquartered in Carlsbad, California. The company holds no government-recognized certifications such as 8(a), HUBZone, or WOSB. Its operational footprint is centered in Southern California, with no public indication of multi-site federal presence or participation in government-wide acquisition contracts. The business model appears aligned with private-sector pharmaceutical R&D rather than direct federal contracting.